BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer. 2004;90:1877-1881. [PMID: 15138464 DOI: 10.1038/sj.bjc.6601839] [Cited by in Crossref: 298] [Cited by in F6Publishing: 281] [Article Influence: 16.6] [Reference Citation Analysis]
Number Citing Articles
1 Galic Jerman K, Kobal B, Jakimovska M, Verdenik I, Cerne K. Control values of ovarian cancer tumor markers and standardisation of a protocol for sampling peritoneal fluid and performing washing during laparoscopy. World J Surg Oncol 2014;12:278. [PMID: 25185697 DOI: 10.1186/1477-7819-12-278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Jan HJ, Lee CC, Shih YL, Hueng DY, Ma HI, Lai JH, Wei HW, Lee HM. Osteopontin regulates human glioma cell invasiveness and tumor growth in mice. Neuro Oncol 2010;12:58-70. [PMID: 20150368 DOI: 10.1093/neuonc/nop013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
3 Darling MR, Gauthier M, Jackson-Boeters L, Daley TD, Chambers AF, Tuck AB. Osteopontin expression in salivary gland tumours. Oral Oncol 2006;42:363-9. [PMID: 16321564 DOI: 10.1016/j.oraloncology.2005.09.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
4 Tang L, Yu W, Wang Y, Li H, Shen Z. Anlotinib inhibits synovial sarcoma by targeting GINS1: a novel downstream target oncogene in progression of synovial sarcoma. Clin Transl Oncol 2019;21:1624-33. [DOI: 10.1007/s12094-019-02090-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
5 Vordermark D, Said HM, Katzer A, Kuhnt T, Hänsgen G, Dunst J, Flentje M, Bache M. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006;6. [DOI: 10.1186/1471-2407-6-207] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.7] [Reference Citation Analysis]
6 Song JY, Lee JK, Lee NW, Yeom BW, Kim SH, Lee KW. Osteopontin expression correlates with invasiveness in cervical cancer. Aust N Z J Obstet Gynaecol 2009;49:434-8. [PMID: 19694703 DOI: 10.1111/j.1479-828X.2009.01027.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
7 Shin T. Osteopontin as a two-sided mediator in acute neuroinflammation in rat models. Acta Histochem 2012;114:749-54. [PMID: 22947282 DOI: 10.1016/j.acthis.2012.08.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
8 Phillips RJ, Helbig KJ, Hoek KHVD, Seth D, Beard MR. Osteopontin increases hepatocellular carcinoma cell growth in a CD44 dependant manner. World J Gastroenterol 2012; 18(26): 3389-3399 [PMID: 22807608 DOI: 10.3748/wjg.v18.i26.3389] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
9 Walker C, Nguyen TM, Jessel S, Alvero AB, Silasi DA, Rutherford T, Draghici S, Mor G. Automated Assay of a Four-Protein Biomarker Panel for Improved Detection of Ovarian Cancer. Cancers (Basel) 2021;13:325. [PMID: 33477343 DOI: 10.3390/cancers13020325] [Reference Citation Analysis]
10 Powell JA, Thomas D, Barry EF, Kok CH, Mcclure BJ, Tsykin A, To LB, Brown A, Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, Haylock DN, Nilsson SK, D'andrea RJ, Lopez AF, Guthridge MA. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood 2009;114:4859-70. [DOI: 10.1182/blood-2009-02-204818] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
11 Saad FA, Salih E, Glimcher MJ. Identification of osteopontin phosphorylation sites involved in bone remodeling and inhibition of pathological calcification. J Cell Biochem 2008;103:852-6. [PMID: 17615552 DOI: 10.1002/jcb.21453] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
12 Varol C, Sagi I. Phagocyte-extracellular matrix crosstalk empowers tumor development and dissemination. FEBS J 2018;285:734-51. [DOI: 10.1111/febs.14317] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
13 Caswell PT, Chan M, Lindsay AJ, McCaffrey MW, Boettiger D, Norman JC. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol 2008;183:143-55. [PMID: 18838556 DOI: 10.1083/jcb.200804140] [Cited by in Crossref: 287] [Cited by in F6Publishing: 269] [Article Influence: 20.5] [Reference Citation Analysis]
14 Liu H, Chen A, Guo F, Yuan L. A short-hairpin RNA targeting osteopontin downregulates MMP-2 and MMP-9 expressions in prostate cancer PC-3 cells. Cancer Lett 2010;295:27-37. [PMID: 20207476 DOI: 10.1016/j.canlet.2010.02.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
15 Hill RP. Targeted treatment: insights from studies of osteopontin and hypoxia. Lancet Oncol 2005;6:733-4. [PMID: 16198974 DOI: 10.1016/S1470-2045(05)70363-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
16 Desai B, Ma T, Zhu J, Chellaiah MA. Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem. 2009;108:272-284. [PMID: 19582779 DOI: 10.1002/jcb.22248] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
17 Natasha T, Kuhn M, Kelly O, Rittling SR. Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone. Am J Pathol 2006;168:551-61. [PMID: 16436669 DOI: 10.2353/ajpath.2006.050480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
18 Spyrou N, Avgerinos KI, Mantzoros CS, Dalamaga M. Classic and Novel Adipocytokines at the Intersection of Obesity and Cancer: Diagnostic and Therapeutic Strategies. Curr Obes Rep 2018;7:260-75. [DOI: 10.1007/s13679-018-0318-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
19 Ahmed M, Sottnik JL, Dancik GM, Sahu D, Hansel DE, Theodorescu D, Schwartz MA. An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression. Cancer Cell 2016;30:432-43. [PMID: 27593345 DOI: 10.1016/j.ccell.2016.08.002] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
20 Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Hölttä E. Osteopontin promotes the invasive growth of melanoma cells by activating integrin αvβ3 and down-regulating tetraspanin CD9. Am J Pathol 2014;184:842-58. [PMID: 24412090 DOI: 10.1016/j.ajpath.2013.11.020] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
21 Jepson MA, Davis MJ, Horton AA, Walker DG. Histochemical and biochemical observations on the cytotoxicity of paracetamol and its effects on glycogen metabolism in rat liver. Toxicology. 1987;47:325-337. [PMID: 3424388 DOI: 10.1002/mc.22153] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhao J, Lu B, Xu H, Tong X, Wu G, Zhang X, Liang A, Cong W, Dai J, Wang H. Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma. Hepatology. 2008;48:265-275. [PMID: 18537194 DOI: 10.1002/hep.22280] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
23 Staibano S, Merolla F, Testa D, Iovine R, Mascolo M, Guarino V, Castellone MD, Di Benedetto M, Galli V, Motta S. OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome. Br J Cancer. 2007;97:1545-1551. [PMID: 17987038 DOI: 10.1038/sj.bjc.6604070] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
24 Menicali E, Moretti S, Voce P, Romagnoli S, Avenia N, Puxeddu E. Intracellular signal transduction and modification of the tumor microenvironment induced by RET/PTCs in papillary thyroid carcinoma. Front Endocrinol (Lausanne) 2012;3:67. [PMID: 22661970 DOI: 10.3389/fendo.2012.00067] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
25 Lizardo MM, Macdonald IC, Tuck AB, Chambers AF. A new breast cancer model for lymphatic metastasis. Cancer Treat Res 2007;135:157-65. [PMID: 17953414 DOI: 10.1007/978-0-387-69219-7_11] [Reference Citation Analysis]
26 Zhang H, Zhong J, Tu Y, Liu B, Chen Z, Luo Y, Tang Y, Xiao F. Integrated Bioinformatics Analysis Identifies Hub Genes Associated with the Pathogenesis and Prognosis of Esophageal Squamous Cell Carcinoma. Biomed Res Int. 2019;2019:2615921. [PMID: 31950035 DOI: 10.1155/2019/2615921] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
27 Rittling SR, Wejse PL, Yagiz K, Warot GA, Hui T. Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels. Br J Cancer 2014;110:1269-77. [PMID: 24473400 DOI: 10.1038/bjc.2014.10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhou X, Zimonjic DB, Park SW, Yang XY, Durkin ME, Popescu NC. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol 2008;32:1285-91. [PMID: 18497990 DOI: 10.3892/ijo_32_6_1285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 22] [Article Influence: 0.1] [Reference Citation Analysis]
29 Pillai K, Akhter J, Chua TC, Morris DL. Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma. Cancer Invest. 2013;31:241-250. [PMID: 23570457 DOI: 10.3109/07357907.2013.784777] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
30 Lei H, Wang H, Juan AH, Ruddle FH. The identification of Hoxc8 target genes. Proc Natl Acad Sci U S A 2005;102:2420-4. [PMID: 15699330 DOI: 10.1073/pnas.0409700102] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 3.8] [Reference Citation Analysis]
31 Courter D, Cao H, Kwok S, Kong C, Banh A, Kuo P, Bouley DM, Vice C, Brustugun OT, Denko NC, Koong AC, Giaccia A, Le QT. The RGD domain of human osteopontin promotes tumor growth and metastasis through activation of survival pathways. PLoS One 2010;5:e9633. [PMID: 20224789 DOI: 10.1371/journal.pone.0009633] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
32 Poggio P, Branchetti E, Grau JB, Lai EK, Gorman RC, Gorman JH 3rd, Sacks MS, Bavaria JE, Ferrari G. Osteopontin-CD44v6 interaction mediates calcium deposition via phospho-Akt in valve interstitial cells from patients with noncalcified aortic valve sclerosis. Arterioscler Thromb Vasc Biol 2014;34:2086-94. [PMID: 25060796 DOI: 10.1161/ATVBAHA.113.303017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
33 Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Chambers AF. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res 2014;16:R8. [PMID: 24451146 DOI: 10.1186/bcr3600] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
34 Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best? Lung Cancer 2011;74:55-60. [PMID: 21397972 DOI: 10.1016/j.lungcan.2011.02.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
35 Das R, Philip S, Mahabeleshwar GH, Bulbule A, Kundu GC. Osteopontin: it’s role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life. 2005;57:441-447. [PMID: 16012053 DOI: 10.1080/15216540500159424] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
36 Poggio P, Grau JB, Field BC, Sainger R, Seefried WF, Rizzolio F, Ferrari G. Osteopontin controls endothelial cell migration in vitro and in excised human valvular tissue from patients with calcific aortic stenosis and controls. J Cell Physiol 2011;226:2139-49. [PMID: 21520066 DOI: 10.1002/jcp.22549] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
37 Wu JC, Sun BS, Ren N, Ye QH, Qin LX. Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. J Cancer Res Clin Oncol. 2010;136:595-601. [PMID: 19834740 DOI: 10.1007/s00432-009-0695-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
38 Finis K, Sültmann H, Ruschhaupt M, Buness A, Helmchen B, Kuner R, Gross M, Fink B, Schirmacher P, Poustka A, Berger I. Analysis of pigmented villonodular synovitis with genome-wide complementary DNA microarray and tissue array technology reveals insight into potential novel therapeutic approaches. Arthritis Rheum 2006;54:1009-19. [DOI: 10.1002/art.21641] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
39 Kiss T, Ecsedi S, Vizkeleti L, Koroknai V, Emri G, Kovács N, Adany R, Balazs M. The role of osteopontin expression in melanoma progression. Tumour Biol 2015;36:7841-7. [PMID: 25944164 DOI: 10.1007/s13277-015-3495-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
40 Lei H, Juan AH, Kim MS, Ruddle FH. Identification of a Hoxc8-regulated transcriptional network in mouse embryo fibroblast cells. Proc Natl Acad Sci U S A 2006;103:10305-9. [PMID: 16793922 DOI: 10.1073/pnas.0603552103] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
41 Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med. 2010;10:71-81. [PMID: 20205680 DOI: 10.2174/156652410791065381] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 7.9] [Reference Citation Analysis]
42 Lee CY, Tien HF, Hou HA, Chou WC, Lin LI. Marrow osteopontin level as a prognostic factor in acute myeloid leukaemia. Br J Haematol 2008;141:736-9. [PMID: 18397342 DOI: 10.1111/j.1365-2141.2008.07082.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
43 Christensen B, Nielsen MS, Haselmann KF, Petersen TE, Sørensen ES. Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J. 2005;390:285-292. [PMID: 15869464 DOI: 10.1042/bj20050341] [Cited by in Crossref: 165] [Cited by in F6Publishing: 73] [Article Influence: 9.7] [Reference Citation Analysis]
44 Sun T, Li P, Sun D, Bu Q, Li G. Prognostic value of osteopontin in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12954. [PMID: 30412113 DOI: 10.1097/MD.0000000000012954] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
45 Ojalvo LS, King W, Cox D, Pollard JW. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol 2009;174:1048-64. [PMID: 19218341 DOI: 10.2353/ajpath.2009.080676] [Cited by in Crossref: 150] [Cited by in F6Publishing: 141] [Article Influence: 11.5] [Reference Citation Analysis]
46 Ding W, Yousefi K, Goncalves S, Goldstein BJ, Sabater AL, Kloosterboer A, Ritter P, Lambert G, Mendez AJ, Shehadeh LA. Osteopontin deficiency ameliorates Alport pathology by preventing tubular metabolic deficits. JCI Insight 2018;3:94818. [PMID: 29563333 DOI: 10.1172/jci.insight.94818] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
47 Kaartinen MT, Murshed M, Karsenty G, Mckee MD. Osteopontin Upregulation and Polymerization by Transglutaminase 2 in Calcified Arteries of Matrix Gla Protein-deficient Mice. J Histochem Cytochem 2007;55:375-86. [DOI: 10.1369/jhc.6a7087.2006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
48 Oura CAL, Mckellar S, Swan DG, Okan E, Shiels BR. Infection of bovine cells by the protozoan parasite Theileria annulata modulates expression of the ISGylation system. Cell Microbiol 2006;8:276-88. [DOI: 10.1111/j.1462-5822.2005.00620.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
49 Malaponte G, Hafsi S, Polesel J, Castellano G, Spessotto P, Guarneri C, Canevari S, Signorelli SS, McCubrey JA, Libra M. Tumor microenvironment in diffuse large B-cell lymphoma: Matrixmetalloproteinases activation is mediated by osteopontin overexpression. Biochim Biophys Acta 2016;1863:483-9. [PMID: 26381542 DOI: 10.1016/j.bbamcr.2015.09.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
50 Vladimirova V, Waha A, Lückerath K, Pesheva P, Probstmeier R. Runx2 is expressed in human glioma cells and mediates the expression of galectin-3. J Neurosci Res. 2008;86:2450-2461. [PMID: 18438928 DOI: 10.1002/jnr.21686] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
51 Gan N, Zou S, Hang W, Yang D, Zhang X, Yin Y. Osteopontin is Critical for Hyperactive mTOR-Induced Tumorigenesis in Oral Squamous Cell Carcinoma. J Cancer 2017;8:1362-70. [PMID: 28638450 DOI: 10.7150/jca.18031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
52 Chen Q, Shou P, Zhang L, Xu C, Zheng C, Han Y, Li W, Huang Y, Zhang X, Shao C, Roberts AI, Rabson AB, Ren G, Zhang Y, Wang Y, Denhardt DT, Shi Y. An osteopontin-integrin interaction plays a critical role in directing adipogenesis and osteogenesis by mesenchymal stem cells. Stem Cells 2014;32:327-37. [PMID: 24123709 DOI: 10.1002/stem.1567] [Cited by in Crossref: 124] [Cited by in F6Publishing: 118] [Article Influence: 15.5] [Reference Citation Analysis]
53 Koro K, Parkin S, Pohorelic B, Yang AD, Narendran A, Egan C, Magliocco A. Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration. Breast Cancer Res Treat 2011;126:73-83. [PMID: 20401631 DOI: 10.1007/s10549-010-0889-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
54 Yang H, Ye X, Zhang X, Li X, Fu Q, Tang Z. Intracellular osteopontin negatively regulates toll-like receptor 4-mediated inflammatory response via regulating GSK3β and 4EBP1 phosphorylation. Cytokine 2018;108:89-95. [PMID: 29587154 DOI: 10.1016/j.cyto.2018.03.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
55 Nakamura T, Shinriki S, Jono H, Ueda M, Nagata M, Guo J, Hayashi M, Yoshida R, Ota T, Ota K, Kawahara K, Nakagawa Y, Yamashita S, Nakayama H, Hiraki A, Shinohara M, Ando Y. Osteopontin-integrin α(v)β(3) axis is crucial for 5-fluorouracil resistance in oral squamous cell carcinoma. FEBS Lett 2015;589:231-9. [PMID: 25497015 DOI: 10.1016/j.febslet.2014.12.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
56 Suzuki M, Mose E, Galloy C, Tarin D. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol 2007;171:682-92. [PMID: 17620367 DOI: 10.2353/ajpath.2007.070232] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
57 Ramaiah SK, Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci. 2008;103:4-13. [PMID: 17890765 DOI: 10.1093/toxsci/kfm246] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 7.9] [Reference Citation Analysis]
58 Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS. Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Res. 2008;10:R22. [PMID: 18328103 DOI: 10.1186/bcr1874] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 5.1] [Reference Citation Analysis]
59 Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011;15:1113-26. [PMID: 21718227 DOI: 10.1517/14728222.2011.594438] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 4.6] [Reference Citation Analysis]
60 Hsu KH, Tsai HW, Lin PW, Hsu YS, Shan YS, Lu PJ. Clinical implication and mitotic effect of CD44 cleavage in relation to osteopontin/CD44 interaction and dysregulated cell cycle protein in gastrointestinal stromal tumor. Ann Surg Oncol 2010;17:2199-212. [PMID: 20146103 DOI: 10.1245/s10434-010-0927-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
61 Lee DH, Kim JY, Lee MK, Lee C, Min JH, Jeong DH, Lee JW, Chu SH, Meyerhardt JA, Ligibel J, Jones LW, Kim NK, Jeon JY. Effects of a 12-week home-based exercise program on the level of physical activity, insulin, and cytokines in colorectal cancer survivors: a pilot study. Support Care Cancer. 2013;21:2537-2545. [PMID: 23636649 DOI: 10.1007/s00520-013-1822-7] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 6.9] [Reference Citation Analysis]
62 Nanci A, Wazen RM, Zalzal SF, Fortin M, Goldberg HA, Hunter GK, Ghitescu D. A Tracer Study with Systemically and Locally Administered Dinitrophenylated Osteopontin. J Histochem Cytochem 2004;52:1591-600. [DOI: 10.1369/jhc.4a6452.2004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
63 Ke H, Chang L, Yang S, Lin H, Li C, Wu D, Wu W. Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations 2011;29:703-9. [DOI: 10.1016/j.urolonc.2009.10.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
64 Zhang X, Ye LH, Zhang XD. A mutant of hepatitis B virus X protein (HBx Delta 127) enhances hepatoma cell migration via osteopontin involving 5-lipoxygenase. Acta Pharmacol Sin 2010;31:593-600. [PMID: 20364155 DOI: 10.1038/aps.2010.36] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
65 Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, Holliday RL, Girvan DP, Scott LA, Postenka CO. Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancer. Am J Pathol. 2006;169:233-246. [PMID: 16816376 DOI: 10.2353/ajpath.2006.051152] [Cited by in Crossref: 71] [Cited by in F6Publishing: 68] [Article Influence: 4.4] [Reference Citation Analysis]
66 Rodenburg W, Pennings JL, van Oostrom CT, Roodbergen M, Kuiper RV, Luijten M, de Vries A. Identification of breast cancer biomarkers in transgenic mouse models: A proteomics approach. Proteomics Clin Appl 2010;4:603-12. [PMID: 21137078 DOI: 10.1002/prca.200900175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
67 Katzav S. Flesh and blood: The story of Vav1, a gene that signals in hematopoietic cells but can be transforming in human malignancies. Cancer Letters 2007;255:241-54. [DOI: 10.1016/j.canlet.2007.04.015] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
68 Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, Wang L, Zhang BH, Liu YK. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006;132:709-717. [PMID: 16786357 DOI: 10.1007/s00432-006-0119-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
69 Brockton NT, Gill SJ, Laborge SL, Paterson AH, Cook LS, Vogel HJ, Shemanko CS, Hanley DA, Magliocco AM, Friedenreich CM. The Breast Cancer to Bone (B2B) Metastases Research Program: a multi-disciplinary investigation of bone metastases from breast cancer. BMC Cancer 2015;15:512. [PMID: 26156521 DOI: 10.1186/s12885-015-1528-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
70 Li C, Zang T, Wrobel K, Huang JT, Nabi G. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer. Anal Bioanal Chem 2015;407:3393-404. [PMID: 25724369 DOI: 10.1007/s00216-015-8569-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
71 Vairo F, Sperb-Ludwig F, Wilke M, Michellin-Tirelli K, Netto C, Neto EC, Schwartz I. Osteopontin: a potential biomarker of Gaucher disease. Ann Hematol 2015;94:1119-25. [PMID: 25875742 DOI: 10.1007/s00277-015-2354-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
72 Filia A, Elliott F, Wind T, Field S, Davies J, Kukalizch K, Randerson-Moor J, Harland M, Bishop DT, Banks RE, Newton-Bishop JA. Plasma osteopontin concentrations in patients with cutaneous melanoma. Oncol Rep 2013;30:1575-80. [PMID: 23934016 DOI: 10.3892/or.2013.2666] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
73 Chen Y, Liersch R, Detmar M. The miR-290-295 cluster suppresses autophagic cell death of melanoma cells. Sci Rep 2012;2:808. [PMID: 23150779 DOI: 10.1038/srep00808] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
74 Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K/Akt pathway. Cancer Sci 2008;99:1901-7. [PMID: 19016748 DOI: 10.1111/j.1349-7006.2008.00911.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 29] [Article Influence: 0.5] [Reference Citation Analysis]
75 Fok TC, Lapointe H, Tuck AB, Chambers AF, Jackson-Boeters L, Daley TD, Darling MR. Expression and localization of osteopontin, homing cell adhesion molecule/CD44, and integrin αvβ3 in mucoepidermoid carcinoma and acinic cell adenocarcinoma of salivary gland origin. Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118:320-9. [PMID: 25151586 DOI: 10.1016/j.oooo.2014.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
76 Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, Li K, Tong X, Dai J, Yao S. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology. 2008;135:956-968. [PMID: 18555021 DOI: 10.1053/j.gastro.2008.05.025] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 6.5] [Reference Citation Analysis]
77 Ferreira LB, Tavares C, Pestana A, Pereira CL, Eloy C, Pinto MT, Castro P, Batista R, Rios E, Sobrinho-Simões M, Gimba ER, Soares P. Osteopontin-a splice variant is overexpressed in papillary thyroid carcinoma and modulates invasive behavior. Oncotarget 2016;7:52003-16. [PMID: 27409830 DOI: 10.18632/oncotarget.10468] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
78 Al-Swiahb JN, Chen CH, Chuang HC, Fang FM, Tasi HT, Chien CY. Clinical, pathological and molecular determinants in squamous cell carcinoma of the oral cavity. Future Oncol 2010;6:837-50. [PMID: 20465394 DOI: 10.2217/fon.10.35] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
79 Ady JW, Desir S, Thayanithy V, Vogel RI, Moreira AL, Downey RJ, Fong Y, Manova-Todorova K, Moore MA, Lou E. Intercellular communication in malignant pleural mesothelioma: properties of tunneling nanotubes. Front Physiol 2014;5:400. [PMID: 25400582 DOI: 10.3389/fphys.2014.00400] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
80 LaGrandeur RG, Singhal M, Bany-Mohammed F, Uy C, Koeppel R, Zaldivar F, Haddad F, Nalbandian A, Donovan P, Cooper DM, Aslam M. Pilot feasibility study to detect mesenchymal stem cell biomarkers of bronchopulmonary dysplasia in the tracheal aspirate fluid of preterm infants. J Neonatal Perinatal Med 2018;11:1-10. [PMID: 29689740 DOI: 10.3233/NPM-181722] [Reference Citation Analysis]
81 Wottawa M, Leisering P, Ahlen Mv, Schnelle M, Vogel S, Malz C, Bordoli MR, Camenisch G, Hesse A, Napp J, Alves F, Kristiansen G, Farhat K, Katschinski DM. Knockdown of prolyl-4-hydroxylase domain 2 inhibits tumor growth of human breast cancer MDA-MB-231 cells by affecting TGF-β1 processing. Int J Cancer 2013;132:2787-98. [PMID: 23225569 DOI: 10.1002/ijc.27982] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
82 Triozzi PL, Singh AD. Blood biomarkers for uveal melanoma. Future Oncol 2012;8:205-15. [PMID: 22335584 DOI: 10.2217/fon.11.150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
83 Rashdan S, Iyengar P, Minna JD, Gerber DE. Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer. Transl Lung Cancer Res 2021;10:3351-68. [PMID: 34430372 DOI: 10.21037/tlcr-21-448] [Reference Citation Analysis]
84 Weismann D, Briese J, Niemann J, Grüneberger M, Adam P, Hahner S, Johanssen S, Liu W, Ezzat S, Saeger W, Bamberger AM, Fassnacht M, Schulte HM, Asa SL, Allolio B, Bamberger CM. Osteopontin stimulates invasion of NCI-h295 cells but is not associated with survival in adrenocortical carcinoma. J Pathol 2009;218:232-40. [PMID: 19326399 DOI: 10.1002/path.2528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
85 Pazolli E, Luo X, Brehm S, Carbery K, Chung JJ, Prior JL, Doherty J, Demehri S, Salavaggione L, Piwnica-Worms D, Stewart SA. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res 2009;69:1230-9. [PMID: 19155301 DOI: 10.1158/0008-5472.CAN-08-2970] [Cited by in Crossref: 89] [Cited by in F6Publishing: 55] [Article Influence: 6.8] [Reference Citation Analysis]
86 Cao L, Fan X, Jing W, Liang Y, Chen R, Liu Y, Zhu M, Jia R, Wang H, Zhang X, Zhang Y, Zhou X, Zhao J, Guo Y. Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-κB-HIF-1α pathway. Oncotarget 2015;6:6627-40. [PMID: 25749383 DOI: 10.18632/oncotarget.3113] [Cited by in Crossref: 42] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
87 Gong M, Lu Z, Fang G, Bi J, Xue X. A small interfering RNA targeting osteopontin as gastric cancer therapeutics. Cancer Lett. 2008;272:148-159. [PMID: 18694621 DOI: 10.1016/j.canlet.2008.07.004] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
88 Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR, Sagebiel RW, Kashani-Sabet M. Osteopontin as a molecular prognostic marker for melanoma. Cancer. 2008;112:144-150. [PMID: 18023025 DOI: 10.1002/cncr.23147] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 5.3] [Reference Citation Analysis]
89 Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14:2037-2044. [PMID: 20597997 DOI: 10.1111/j.1582-4934.2010.01115.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 119] [Article Influence: 9.7] [Reference Citation Analysis]
90 Hao C, Wang Z, Gu Y, Jiang WG, Cheng S. Prognostic Value of Osteopontin Splice Variant-c Expression in Breast Cancers: A Meta-Analysis. Biomed Res Int 2016;2016:7310694. [PMID: 27462610 DOI: 10.1155/2016/7310694] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
91 Larsson O, Perlman DM, Fan D, Reilly CS, Peterson M, Dahlgren C, Liang Z, Li S, Polunovsky VA, Wahlestedt C, Bitterman PB. Apoptosis resistance downstream of eIF4E: posttranscriptional activation of an anti-apoptotic transcript carrying a consensus hairpin structure. Nucleic Acids Res 2006;34:4375-86. [PMID: 16936314 DOI: 10.1093/nar/gkl558] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
92 Hsieh Y, van der Heyde H, Oh E, Guan J, Chang P. Osteopontin mediates tumorigenic transformation of a preneoplastic murine cell line by suppressing anoikis: An Arg-Gly-Asp-dependent-focal adhesion kinase-caspase-8 axis: OSTEOPONTIN SUPPRESSES ANOIKIS OF JB6 CELLS. Mol Carcinog 2015;54:379-92. [DOI: 10.1002/mc.22108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
93 Kao E, Wang C, Lin W, Chu C, Tseng T. Effects of polyphenols derived from fruit of Crataegus pinnatifida on cell transformation, dermal edema and skin tumor formation by phorbol ester application. Food and Chemical Toxicology 2007;45:1795-804. [DOI: 10.1016/j.fct.2007.03.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
94 Matsuzaki H, Shima K, Muramatsu T, Ro Y, Hashimoto S, Shibahara T, Shimono M. Osteopontin as biomarker in early invasion by squamous cell carcinoma in tongue. J Oral Pathol Med 2007;36:30-4. [PMID: 17181739 DOI: 10.1111/j.1600-0714.2006.00493.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
95 Song G, Ming Y, Mao Y, Bao S, Ouyang G. Osteopontin prevents curcumin-induced apoptosis and promotes survival through Akt activation via alpha v beta 3 integrins in human gastric cancer cells. Exp Biol Med (Maywood). 2008;233:1537-1545. [PMID: 18849546 DOI: 10.3181/0805-rm-164] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
96 Li Y, Li L, Wang JT, Kan X, Lu JG. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis. Med Oncol 2012;29:1429-34. [PMID: 21706367 DOI: 10.1007/s12032-011-0012-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
97 Chien CY, Su CY, Chuang HC, Fang FM, Huang HY, Chen CH, Chen CM, Huang CC. Comprehensive study on the prognostic role of osteopontin expression in oral squamous cell carcinoma. Oral Oncol 2009;45:798-802. [PMID: 19213594 DOI: 10.1016/j.oraloncology.2008.12.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
98 Khan SA, Cook AC, Kappil M, Günthert U, Chambers AF, Tuck AB, Denhardt DT. Enhanced cell surface CD44 variant (v6, v9) expression by osteopontin in breast cancer epithelial cells facilitates tumor cell migration: novel post-transcriptional, post-translational regulation. Clin Exp Metastasis 2005;22:663-73. [PMID: 16691370 DOI: 10.1007/s10585-006-9007-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 4.5] [Reference Citation Analysis]
99 Kim SM, Park YY, Park ES, Cho JY, Izzo JG, Zhang D, Kim SB, Lee JH, Bhutani MS, Swisher SG, Wu X, Coombes KR, Maru D, Wang KK, Buttar NS, Ajani JA, Lee JS. Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One. 2010;5:e15074. [PMID: 21152079 DOI: 10.1371/journal.pone.0015074] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
100 Karpinsky G, Krawczyk MA, Izycka-Swieszewska E, Fatyga A, Budka A, Balwierz W, Sobol G, Zalewska-Szewczyk B, Rychlowska-Pruszynska M, Klepacka T, Dembowska-Baginska B, Kazanowska B, Gabrych A, Bien E. Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor. J Cancer Res Clin Oncol 2018;144:519-29. [PMID: 29332262 DOI: 10.1007/s00432-018-2580-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
101 Tang M, Chen R, Wang H, Sun G, Yin F, Liang B, Yang Y, Sharen G, Wei H, Zhou X, Huang G, Zhao J. Obesity-Induced Methylation of Osteopontin Contributes to Adipogenic Differentiation of Adipose-Derived Mesenchymal Stem Cells. Stem Cells Int 2019;2019:1238153. [PMID: 30911298 DOI: 10.1155/2019/1238153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
102 Hahne JC, Meyer SR, Kranke P, Dietl J, Guckenberger M, Polat B, Hönig A. Studies on the role of osteopontin-1 in endometrial cancer cell lines. Strahlenther Onkol 2013;189:1040-8. [PMID: 24126938 DOI: 10.1007/s00066-013-0434-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
103 Liu H, Chen A, Guo F, Yuan L. Influence of osteopontin short hairpin RNA on the proliferation and invasion of human renal cancer cells. J Huazhong Univ Sci Technolog Med Sci 2010;30:61-8. [PMID: 20155457 DOI: 10.1007/s11596-011-0111-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
104 Miyatani K, Saito H, Kono Y, Murakami Y, Kuroda H, Matsunaga T, Fukumoto Y, Osaki T, Ashida K, Fujiwara Y. Combined analysis of the pre- and postoperative neutrophil–lymphocyte ratio predicts the outcomes of patients with gastric cancer. Surg Today 2018;48:300-7. [DOI: 10.1007/s00595-017-1587-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
105 Jeong NH, Lee JM, Lee SK. Current status in the management of uterine corpus cancer in Korea. J Gynecol Oncol 2010;21:151-62. [PMID: 20922137 DOI: 10.3802/jgo.2010.21.3.151] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
106 Kyjacova L, Saup R, Rönsch K, Wallbaum S, Dukowic-Schulze S, Foss A, Scherer SD, Rothley M, Neeb A, Grau N, Thiele W, Thaler S, Cremers N, Sticht C, Gretz N, Garvalov BK, Utikal J, Sleeman JP. IER2-induced senescence drives melanoma invasion through osteopontin. Oncogene 2021;40:6494-512. [PMID: 34611309 DOI: 10.1038/s41388-021-02027-6] [Reference Citation Analysis]
107 Hass HG, Nehls O, Jobst J, Frilling A, Vogel U, Kaiser S. Identification of osteopontin as the most consistently over-expressed gene in intrahepatic cholangiocarcinoma: Detection by oligonucleotide microarray and real-time PCR analysis. World J Gastroenterol 2008; 14(16): 2501-2510 [PMID: 18442196 DOI: 10.3748/wjg.14.2501] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
108 Kijewska M, Kocyk M, Kloss M, Stepniak K, Korwek Z, Polakowska R, Dabrowski M, Gieryng A, Wojtas B, Ciechomska IA, Kaminska B. The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma. Oncotarget 2017;8:16340-55. [PMID: 28030801 DOI: 10.18632/oncotarget.14092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
109 Peng L, Guo Y, Zhou Y, Dai J, Wang H. Inhibition of Breast Cancer Metastasis and Angiogenesis by Antiosteopontin Single-Chain Fv-Fc Fusion Protein. Neoplasia 2009;11:509-19. [DOI: 10.1593/neo.81622] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
110 Cristaudo A, Bonotti A, Simonini S, Bruno R, Foddis R. Soluble markers for diagnosis of malignant pleural mesothelioma. Biomarkers in Medicine 2011;5:261-73. [DOI: 10.2217/bmm.11.18] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
111 Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, Olsen A, Tjønneland A, Baglietto L, Severi G, Boutron-Ruault MC, Turzanski-Fortner R, Kaaks R, Boeing H, Aleksandrova K, Trichopoulou A, Lagiou P, Bamia C, Pala V, Palli D, Mattiello A, Tumino R, Naccarati A, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Quirós JR, Agudo A, Sánchez-Cantalejo E, Ardanaz E, Gavrila D, Dorronsoro M, Werner M, Hemmingsson O, Ohlsson B, Sjöberg K, Wareham NJ, Khaw KT, Bradbury KE, Gunter MJ, Cross AJ, Riboli E, Jenab M, Hainaut P, Beretta L. Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population. Cancer Prev Res (Phila) 2016;9:758-65. [PMID: 27339170 DOI: 10.1158/1940-6207.CAPR-15-0434] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
112 Pai M, Kuo Y, Chiang EI, Tang F. S -Allylcysteine inhibits tumour progression and the epithelial–mesenchymal transition in a mouse xenograft model of oral cancer. Br J Nutr 2012;108:28-38. [DOI: 10.1017/s0007114511005307] [Cited by in Crossref: 20] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
113 Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, Chambers AF, Allan AL. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat 2008;112:243-54. [PMID: 18097747 DOI: 10.1007/s10549-007-9865-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
114 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
115 Henry A, Nokin MJ, Leroi N, Lallemand F, Lambert J, Goffart N, Roncarati P, Bianchi E, Peixoto P, Blomme A, Turtoi A, Peulen O, Habraken Y, Scholtes F, Martinive P, Delvenne P, Rogister B, Castronovo V, Bellahcène A. New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity. Oncotarget 2016;7:63708-21. [PMID: 27563812 DOI: 10.18632/oncotarget.11483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
116 Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW. Microarray analysis of normal cervix, carcinoma in situ , and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. Int J Gynecol Cancer 2008;18:1051-9. [DOI: 10.1111/j.1525-1438.2007.01164.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
117 Camalier CE, Young MR, Bobe G, Perella CM, Colburn NH, Beck GR. Elevated phosphate activates N-ras and promotes cell transformation and skin tumorigenesis. Cancer Prev Res (Phila). 2010;3:359-370. [PMID: 20145188 DOI: 10.1158/1940-6207.capr-09-0068] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
118 Klupczynska A, Dereziński P, Matysiak J, Dyszkiewicz W, Kasprzyk M, Kokot ZJ. Determination of 16 serum angiogenic factors in stage I non-small cell lung cancer using a bead-based multiplex immunoassay. Biomedicine & Pharmacotherapy 2017;88:1031-7. [DOI: 10.1016/j.biopha.2017.01.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
119 Han SS, Lee SJ, Kim WJ, Ryu DR, Won JY, Park S, Cheon MJ. Plasma osteopontin is a useful diagnostic biomarker for advanced non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2013;75:104-10. [PMID: 24101934 DOI: 10.4046/trd.2013.75.3.104] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
120 Lin CN, Wang CJ, Chao YJ, Lai MD, Shan YS. The significance of the co-existence of osteopontin and tumor-associated macrophages in gastric cancer progression. BMC Cancer 2015;15:128. [PMID: 25872762 DOI: 10.1186/s12885-015-1114-3] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
121 Bjørndal K, Larsen SR, Godballe C, Krogdahl A. Osteopontin expression in salivary gland carcinomas: Osteopontin expression in salivary gland carcinomas. Journal of Oral Pathology & Medicine 2011;40:451-5. [DOI: 10.1111/j.1600-0714.2010.00964.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
122 Saghiri MA, Asatourian A, Orangi J, Sorenson CM, Sheibani N. Functional role of inorganic trace elements in angiogenesis—Part I: N, Fe, Se, P, Au, and Ca. Critical Reviews in Oncology/Hematology 2015;96:129-42. [DOI: 10.1016/j.critrevonc.2015.05.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
123 Rademakers SE, Span PN, Kaanders JH, Sweep FC, van der Kogel AJ, Bussink J. Molecular aspects of tumour hypoxia. Mol Oncol. 2008;2:41-53. [PMID: 19383328 DOI: 10.1016/j.molonc.2008.03.006] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 7.6] [Reference Citation Analysis]
124 Cook AC, Tuck AB, Mccarthy S, Turner JG, Irby RB, Bloom GC, Yeatman TJ, Chambers AF. Osteopontin induces multiple changes in gene expression that reflect the six “hallmarks of cancer” in a model of breast cancer progression. Mol Carcinog 2005;43:225-36. [DOI: 10.1002/mc.20105] [Cited by in Crossref: 75] [Cited by in F6Publishing: 70] [Article Influence: 4.4] [Reference Citation Analysis]
125 Kazanecki CC, Uzwiak DJ, Denhardt DT. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J Cell Biochem. 2007;102:912-924. [PMID: 17910028 DOI: 10.1002/jcb.21558] [Cited by in Crossref: 188] [Cited by in F6Publishing: 185] [Article Influence: 13.4] [Reference Citation Analysis]
126 Sedivy R, Kalipciyan M, Mazal PR, Wolf B, Wrba F, Karner-hanusch J, Mühlbacher F, Mader RM. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis. Cancer Detection and Prevention 2005;29:8-14. [DOI: 10.1016/j.cdp.2004.10.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
127 Ang C, Chambers AF, Tuck AB, Winquist E, Izawa JI. Plasma osteopontin levels are predictive of disease stage in patients with transitional cell carcinoma of the bladder. BJU Int 2005;96:803-5. [PMID: 16153205 DOI: 10.1111/j.1464-410X.2005.05716.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
128 Liu YJ, Zhang DQ, Sui XM, Tian W. Overexpression of human osteopontin increases cell proliferation and migration in human embryo kidney-293 cells. Cell Mol Biol Lett 2009;14:670-8. [PMID: 19562270 DOI: 10.2478/s11658-009-0027-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
129 Bacac M, Migliavacca E, Stehle J, Mckee T, Delorenzi M, Coindre J, Guillou L, Stamenkovic I. A gene expression signature that distinguishes desmoid tumours from nodular fasciitis. J Pathol 2006;208:543-53. [DOI: 10.1002/path.1915] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
130 Vantyghem SA, Allan AL, Postenka CO, Al-Katib W, Keeney M, Tuck AB, Chambers AF. A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis 2005;22:351-61. [PMID: 16170671 DOI: 10.1007/s10585-005-0745-1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 2.6] [Reference Citation Analysis]
131 Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008;3:569-85. [PMID: 19649148 DOI: 10.1586/17469872.3.5.569] [Cited by in Crossref: 139] [Cited by in F6Publishing: 131] [Article Influence: 17.4] [Reference Citation Analysis]
132 Durrans A, Gao D, Gupta R, Fischer KR, Choi H, El Rayes T, Ryu S, Nasar A, Spinelli CF, Andrews W, Elemento O, Nolan D, Stiles B, Rafii S, Narula N, Davuluri R, Altorki NK, Mittal V. Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. PLoS One 2015;10:e0129123. [PMID: 26046767 DOI: 10.1371/journal.pone.0129123] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
133 Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD, Wong W, Saenger YM. Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. Am J Clin Dermatol 2020;21:1-11. [PMID: 31602560 DOI: 10.1007/s40257-019-00475-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
134 Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007;56:782-789. [PMID: 17148500 DOI: 10.1136/gut.2006.109868] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 4.4] [Reference Citation Analysis]
135 Rashid AB, Grossniklaus HE. Clinical, pathologic, and imaging features and biological markers of uveal melanoma. Methods Mol Biol 2014;1102:397-425. [PMID: 24258990 DOI: 10.1007/978-1-62703-727-3_21] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
136 El-din Bessa SS, Elwan NM, Suliman GAM, El-shourbagy SH. Clinical Significance of Plasma Osteopontin Level in Egyptian Patients with Hepatitis C Virus-related Hepatocellular Carcinoma. Archives of Medical Research 2010;41:541-7. [DOI: 10.1016/j.arcmed.2010.10.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
137 Thomas LE, Winston J, Rad E, Mort M, Dodd KM, Tee AR, McDyer F, Moore S, Cooper DN, Upadhyaya M. Evaluation of copy number variation and gene expression in neurofibromatosis type-1-associated malignant peripheral nerve sheath tumours. Hum Genomics 2015;9:3. [PMID: 25884485 DOI: 10.1186/s40246-015-0025-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
138 Subraman V, Thiyagarajan M, Malathi N, Rajan ST. OPN -Revisited. J Clin Diagn Res. 2015;9:ZE10-ZE13. [PMID: 26266236 DOI: 10.7860/jcdr/2015/12872.6111] [Cited by in Crossref: 12] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
139 He L, Wang Y. Association of OPN rs11730582 polymorphism with cancer risk: a meta-analysis. Onco Targets Ther 2016;9:1275-80. [PMID: 27022284 DOI: 10.2147/OTT.S94425] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
140 Soikkeli J, Podlasz P, Yin M, Nummela P, Jahkola T, Virolainen S, Krogerus L, Heikkilä P, von Smitten K, Saksela O, Hölttä E. Metastatic outgrowth encompasses COL-I, FN1, and POSTN up-regulation and assembly to fibrillar networks regulating cell adhesion, migration, and growth. Am J Pathol 2010;177:387-403. [PMID: 20489157 DOI: 10.2353/ajpath.2010.090748] [Cited by in Crossref: 74] [Cited by in F6Publishing: 73] [Article Influence: 6.2] [Reference Citation Analysis]
141 Kato N, Motoyama T. Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression. Histopathology 2008;52:682-8. [PMID: 18393978 DOI: 10.1111/j.1365-2559.2008.03006.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
142 Wolosz D, Walczak A, Wilczynski GM, Szparecki G, Wilczek E, Gornicka B. Deleted in liver cancer 1 expression and localization in hepatocellular carcinoma tissue sections. Oncol Lett 2014;8:785-8. [PMID: 25013499 DOI: 10.3892/ol.2014.2216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
143 Deangelis T, Quong A, Morrione A, Baserga R. Growth of v-src-transformed cells in serum-free medium through the induction of growth factors. J Cell Physiol 2013;228:1482-6. [PMID: 23254450 DOI: 10.1002/jcp.24303] [Reference Citation Analysis]
144 Huo Y, Su T, Cai Q, Macara IG. An In Vivo Gain-of-Function Screen Identifies the Williams-Beuren Syndrome Gene GTF2IRD1 as a Mammary Tumor Promoter. Cell Rep 2016;15:2089-96. [PMID: 27239038 DOI: 10.1016/j.celrep.2016.05.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
145 Gu M, Zheng X. Osteopontin and vasculogenic mimicry formation are associated with response to neoadjuvant chemotherapy in advanced breast cancer. Onco Targets Ther 2017;10:4121-7. [PMID: 28860821 DOI: 10.2147/OTT.S129414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
146 Dai J, Peng L, Fan K, Wang H, Wei R, Ji G, Cai J, Lu B, Li B, Zhang D, Kang Y, Tan M, Qian W, Guo Y. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 2009;28:3412-22. [PMID: 19597469 DOI: 10.1038/onc.2009.189] [Cited by in Crossref: 176] [Cited by in F6Publishing: 176] [Article Influence: 13.5] [Reference Citation Analysis]
147 Zollo M, Di Dato V, Spano D, De Martino D, Liguori L, Marino N, Vastolo V, Navas L, Garrone B, Mangano G. Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis. 2012;29:585-601. [PMID: 22484917 DOI: 10.1007/s10585-012-9473-5] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
148 Bucciarelli E, Sidoni A, Bellezza G, Cavaliere A, Brachelente G, Costa G, Chaplet M, Castronovo V, Bellahcène A. Low dentin matrix protein 1 expression correlates with skeletal metastases development in breast cancer patients and enhances cell migratory capacity in vitro. Breast Cancer Res Treat 2007;105:95-104. [PMID: 17136477 DOI: 10.1007/s10549-006-9436-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
149 McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, Reinhardt F, Harris LN, Hylander BL, Repasky EA, Weinberg RA. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008;133:994-1005. [PMID: 18555776 DOI: 10.1016/j.cell.2008.04.045] [Cited by in Crossref: 304] [Cited by in F6Publishing: 271] [Article Influence: 21.7] [Reference Citation Analysis]
150 Schedlbauer A, Coudevylle N, Auer R, Kloiber K, Tollinger M, Konrat R. Autocorrelation analysis of NOESY data provides residue compactness for folded and unfolded proteins. J Am Chem Soc 2009;131:6038-9. [PMID: 19364097 DOI: 10.1021/ja8074067] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
151 Wilson MJ, Liaw L, Koopman P. Osteopontin and related SIBLING glycoprotein genes are expressed by Sertoli cells during mouse testis development. Dev Dyn 2005;233:1488-95. [DOI: 10.1002/dvdy.20456] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
152 Komorowski J, Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K, Swiętoslawski J, Stepien H. Systemic blood osteopontin, endostatin, and E-selectin concentrations after vertical banding surgery in severely obese adults. Cytokine 2011;55:56-61. [PMID: 21486700 DOI: 10.1016/j.cyto.2011.03.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
153 Arnst JL, Beck GR Jr. Modulating phosphate consumption, a novel therapeutic approach for the control of cancer cell proliferation and tumorigenesis. Biochem Pharmacol 2021;183:114305. [PMID: 33129806 DOI: 10.1016/j.bcp.2020.114305] [Reference Citation Analysis]
154 Whalen KA, Weber GF, Benjamin TL, Schaffhausen BS. Polyomavirus middle T antigen induces the transcription of osteopontin, a gene important for the migration of transformed cells. J Virol 2008;82:4946-54. [PMID: 18337582 DOI: 10.1128/JVI.02650-07] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
155 Huang J, Sheng HH, Shen T, Hu YJ, Xiao HS, Zhang Q, Zhang QH, Han ZG. Correlation between genomic DNA copy number alterations and transcriptional expression in hepatitis B virus-associated hepatocellular carcinoma. FEBS Lett 2006;580:3571-81. [PMID: 16750200 DOI: 10.1016/j.febslet.2006.05.032] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
156 Jin F, Jiang K, Ji S, Wang L, Ni Z, Huang F, Li C, Chen R, Zhang H, Hu Z, Zha X. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex. Hum Mol Genet 2017;26:407-19. [PMID: 28013293 DOI: 10.1093/hmg/ddw397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
157 Matusan K, Dordevic G, Mozetic V, Lucin K. Expression of osteopontin and CD44 molecule in papillary renal cell tumors. Pathol Oncol Res 2005;11:108-13. [PMID: 15999156 DOI: 10.1007/BF02893377] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
158 Reiniger IW, Wolf A, Welge-Lüssen U, Mueller AJ, Kampik A, Schaller UC. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study. Am J Ophthalmol 2007;143:705-7. [PMID: 17386288 DOI: 10.1016/j.ajo.2006.11.040] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
159 Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW, Kim TY, Im SA, Kim TY, Bang YJ, Oh DY. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer. Gastric Cancer. 2017;20:254-262. [PMID: 27147244 DOI: 10.1007/s10120-016-0613-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
160 Stepien T, Jurczynska J, Lawnicka H, Stepien H, Krupinski R, Kolomecki K, Kuzdak K, Komorowski J. Osteopontin and endostatin concentrations in peripheral blood of patients with adrenal tumors undergoing unilateral adrenalectomy. Eur Surg Res 2011;47:168-72. [PMID: 21968021 DOI: 10.1159/000330749] [Reference Citation Analysis]
161 Song G, Ouyang G, Mao Y, Ming Y, Bao S, Hu T. Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation. J Cell Mol Med. 2009;13:1706-1718. [PMID: 19602039 DOI: 10.1111/j.1582-4934.2008.00540.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 4.0] [Reference Citation Analysis]
162 Mateos B, Konrat R, Pierattelli R, Felli IC. NMR Characterization of Long-Range Contacts in Intrinsically Disordered Proteins from Paramagnetic Relaxation Enhancement in 13 C Direct-Detection Experiments. Chembiochem 2019;20:335-9. [PMID: 30407719 DOI: 10.1002/cbic.201800539] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
163 Liu W, Li Z, Luo Q, Lai Y, Zhang J, Chen F, Shi J, Li H, Xiong G, Xu G, Wang H. The elevated expression of osteopontin and vascular endothelial growth factor in sinonasal inverted papilloma and its relationship with clinical severity. Am J Rhinol Allergy 2011;25:313-7. [PMID: 22186244 DOI: 10.2500/ajra.2011.25.3662] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
164 Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-60. [PMID: 16456138 DOI: 10.1164/rccm.200511-1789OC] [Cited by in Crossref: 161] [Cited by in F6Publishing: 53] [Article Influence: 10.1] [Reference Citation Analysis]
165 Jin H, Valverde P, Chen J. Cloning of hamster osteopontin and expression distribution in normal tissues and experimentally induced oral squamous-cell carcinoma. Arch Oral Biol 2006;51:236-45. [PMID: 16095557 DOI: 10.1016/j.archoralbio.2005.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
166 Lin J, Myers AL, Wang Z, Nancarrow DJ, Ferrer-Torres D, Handlogten A, Leverenz K, Bao J, Thomas DG, Wang TD, Orringer MB, Reddy RM, Chang AC, Beer DG, Lin L. Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget 2015;6:22239-57. [PMID: 26068949 DOI: 10.18632/oncotarget.4161] [Cited by in Crossref: 28] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
167 Platzer G, Schedlbauer A, Chemelli A, Ozdowy P, Coudevylle N, Auer R, Kontaxis G, Hartl M, Miles AJ, Wallace BA, Glatter O, Bister K, Konrat R. The metastasis-associated extracellular matrix protein osteopontin forms transient structure in ligand interaction sites. Biochemistry 2011;50:6113-24. [PMID: 21609000 DOI: 10.1021/bi200291e] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
168 Grimm G, Vila G, Bieglmayer C, Riedl M, Luger A, Clodi M. Changes in osteopontin and in biomarkers of bone turnover during human endotoxemia. Bone 2010;47:388-91. [PMID: 20420943 DOI: 10.1016/j.bone.2010.04.602] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
169 Hartl M, Karagiannidis AI, Bister K. Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis. Oncogene 2006;25:4043-55. [DOI: 10.1038/sj.onc.1209441] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
170 Konno S, Hoshi T, Taira T, Plunkett B, Huang SK. Endotoxin contamination contributes to the in vitro cytokine-inducing activity of osteopontin preparations. J Interferon Cytokine Res 2005;25:277-82. [PMID: 15871665 DOI: 10.1089/jir.2005.25.277] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
171 Streuli I, Santulli P, Chouzenoux S, Chapron C, Batteux F. Serum Osteopontin Levels Are Decreased in Focal Adenomyosis. Reprod Sci 2017;24:773-82. [DOI: 10.1177/1933719116669054] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
172 Lennon AM, Goggins M. Diagnostic and Therapeutic Response Markers. Pancreatic Cancer. New York: Springer; 2010. pp. 675-701. [DOI: 10.1007/978-0-387-77498-5_28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
173 Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J Cell Commun Signal. 2011;5:111-122. [PMID: 21516514 DOI: 10.1007/s12079-011-0130-6] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
174 Banach P, Dereziński P, Matysiak J, Horała A, Swiatly A, Jasiński P, Kokot ZJ, Nowak-Markwitz E. Serum angiogenesis profile in gestational trophoblastic neoplasm using multiplex immunoassay. Life Sci 2018;211:25-30. [PMID: 30195618 DOI: 10.1016/j.lfs.2018.08.070] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
175 Li B, Chen D, Li W, Xiao D. 20(S)-Protopanaxadiol saponins inhibit SKOV3 cell migration. Oncol Lett 2016;11:1693-8. [PMID: 26998063 DOI: 10.3892/ol.2016.4155] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
176 Zhu M, He H, Meng Q, Zhu Y, Ye X, Xu N, Yu J. Osteopontin sequence modified mesoporous calcium silicate scaffolds to promote angiogenesis in bone tissue regeneration. J Mater Chem B 2020;8:5849-61. [PMID: 32530014 DOI: 10.1039/d0tb00527d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
177 Cho H, Kang ES, Kim YT, Kim JH. Diagnostic and prognostic impact of osteopontin expression in endometrial cancer. Cancer Invest 2009;27:313-23. [PMID: 19194826 DOI: 10.1080/07357900802375738] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
178 Minai-Tehrani A, Chang SH, Kwon JT, Hwang SK, Kim JE, Shin JY, Yu KN, Park SJ, Jiang HL, Kim JH, Hong SH, Kang B, Kim D, Chae CH, Lee KH, Beck GR Jr, Cho MH. Aerosol delivery of lentivirus-mediated O-glycosylation mutant osteopontin suppresses lung tumorigenesis in K-ras (LA1) mice. Cell Oncol (Dordr) 2013;36:15-26. [PMID: 23070870 DOI: 10.1007/s13402-012-0107-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
179 Shimizu S, Saito H, Kono Y, Murakami Y, Shishido Y, Miyatani K, Matsunaga T, Fukumoto Y, Fujiwara Y. The prognostic significance of the comprehensive complication index in patients with gastric cancer. Surg Today 2019;49:913-20. [PMID: 31147763 DOI: 10.1007/s00595-019-01828-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
180 Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 2005;1:37-50. [PMID: 16555974 DOI: 10.1517/14796694.1.1.37] [Cited by in Crossref: 134] [Cited by in F6Publishing: 113] [Article Influence: 8.4] [Reference Citation Analysis]
181 Rabjerg M, Bjerregaard H, Halekoh U, Jensen BL, Walter S, Marcussen N. Molecular characterization of clear cell renal cell carcinoma identifies CSNK2A1, SPP1 and DEFB1 as promising novel prognostic markers. APMIS 2016;124:372-83. [DOI: 10.1111/apm.12519] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
182 Karpinsky G, Fatyga A, Krawczyk MA, Chamera M, Sande N, Szmyd D, Izycka-swieszewska E, Bien E. Osteopontin: its potential role in cancer of children and young adults. Biomarkers in Medicine 2017;11:389-402. [DOI: 10.2217/bmm-2016-0308] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
183 Ostheimer C, Gunther S, Bache M, Vordermark D, Multhoff G. Dynamics of Heat Shock Protein 70 Serum Levels As a Predictor of Clinical Response in Non-Small-Cell Lung Cancer and Correlation with the Hypoxia-Related Marker Osteopontin. Front Immunol 2017;8:1305. [PMID: 29093708 DOI: 10.3389/fimmu.2017.01305] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
184 Christensen B, Kazanecki CC, Petersen TE, Rittling SR, Denhardt DT, Sørensen ES. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J Biol Chem. 2007;282:19463-19472. [PMID: 17500062 DOI: 10.1074/jbc.m703055200] [Cited by in Crossref: 105] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]
185 Bande Rodríguez MF, Fernandez Marta B, Lago Baameiro N, Santiago-Varela M, Silva-Rodríguez P, Blanco-Teijeiro MJ, Pardo Perez M, Piñeiro Ces A. Blood Biomarkers of Uveal Melanoma: Current Perspectives. Clin Ophthalmol 2020;14:157-69. [PMID: 32021081 DOI: 10.2147/OPTH.S199064] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
186 Kadkol SS, Lin AY, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis AJ, Folberg R, Pe'er J. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Invest Ophthalmol Vis Sci 2006;47:802-6. [PMID: 16505010 DOI: 10.1167/iovs.05-0422] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
187 Zaravinos A, Volanis D, Lambrou GI, Delakas D, Spandidos DA. Role of the angiogenic components, VEGFA, FGF2, OPN and RHOC, in urothelial cell carcinoma of the urinary bladder. Oncol Rep 2012;28:1159-66. [PMID: 22895562 DOI: 10.3892/or.2012.1948] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
188 Huang X, Qian Y, Wu H, Xie X, Zhou Q, Wang Y, Kuang W, Shen L, Li K, Su J, Shen L, Chen X. Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma. J Histochem Cytochem 2015;63:88-98. [PMID: 25380749 DOI: 10.1369/0022155414561329] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
189 Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. Cancer Immunol Immunother 2015;64:769-76. [DOI: 10.1007/s00262-015-1686-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
190 Liu SJ, Zhang DQ, Sui XM, Zhang L, Cai ZW, Sun LQ, Liu YJ, Xue Y, Hu GF. The inhibition of in vivo tumorigenesis of osteosarcoma (OS)-732 cells by antisense human osteopontin RNA. Cell Mol Biol Lett 2008;13:11-9. [PMID: 17952379 DOI: 10.2478/s11658-007-0031-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
191 Nazneen F, Bai F. The Roles of Osteopontin in the Pathogenesis of West Nile Encephalitis. Vaccines (Basel) 2020;8:E748. [PMID: 33317005 DOI: 10.3390/vaccines8040748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Yu X, Li Z, Wu WK. TIP30: A Novel Tumor-Suppressor Gene. Oncol Res 2014;22:339-48. [PMID: 26629947 DOI: 10.3727/096504015X14424348426116] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
193 Partridge CR, He Q, Brun M, Ramos KS. Genetic networks of cooperative redox regulation of osteopontin. Matrix Biol 2008;27:462-74. [PMID: 18378437 DOI: 10.1016/j.matbio.2008.01.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
194 Chang PL, Harkins L, Hsieh YH, Hicks P, Sappayatosok K, Yodsanga S, Swasdison S, Chambers AF, Elmets CA, Ho KJ. Osteopontin expression in normal skin and non-melanoma skin tumors. J Histochem Cytochem 2008;56:57-66. [PMID: 17938278 DOI: 10.1369/jhc.7A7325.2007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
195 Arikök AT, Onder E, Seçkin H, Kaçar A, Fesli R, Oğuz AS, Alper M. Osteopontin expressions correlate with WHO grades and predict recurrence in meningiomas. Brain Tumor Pathol 2014;31:94-100. [PMID: 23793814 DOI: 10.1007/s10014-013-0152-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
196 Yoo M, Xu X, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin Reductase 1 Deficiency Reverses Tumor Phenotype and Tumorigenicity of Lung Carcinoma Cells. Journal of Biological Chemistry 2006;281:13005-8. [DOI: 10.1074/jbc.c600012200] [Cited by in Crossref: 203] [Cited by in F6Publishing: 78] [Article Influence: 12.7] [Reference Citation Analysis]
197 Cabia B, Andrade S, Carreira MC, Casanueva FF, Crujeiras AB. A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis. Obes Rev 2016;17:361-76. [PMID: 26914773 DOI: 10.1111/obr.12377] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 8.0] [Reference Citation Analysis]
198 Saurel CA, Personett DA, Edenfield BH, Solberg LA, Jiang L, Menke DM, Tun HW. Molecular analysis of intravascular large B-cell lymphoma with neoangiogenesis. Br J Haematol 2011;152:234-6. [PMID: 20955396 DOI: 10.1111/j.1365-2141.2010.08354.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
199 Matusan-ilijas K, Behrem S, Jonjic N, Zarkovic K, Lucin K. Osteopontin Expression Correlates with Angiogenesis and Survival in Malignant Astrocytoma. Pathol Oncol Res 2008;14:293-8. [DOI: 10.1007/s12253-008-9058-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
200 Liu F, Bai C, Guo Z. The prognostic value of osteopontin in limited-stage small cell lung cancer patients and its mechanism. Oncotarget 2017;8:70084-96. [PMID: 29050263 DOI: 10.18632/oncotarget.19589] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
201 Iida T, Wagatsuma K, Hirayama D, Nakase H. Is Osteopontin a Friend or Foe of Cell Apoptosis in Inflammatory Gastrointestinal and Liver Diseases? Int J Mol Sci 2017;19:E7. [PMID: 29267211 DOI: 10.3390/ijms19010007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
202 Colin C, Baeza N, Bartoli C, Fina F, Eudes N, Nanni I, Martin PM, Ouafik L, Figarella-Branger D. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 2006;25:2818-26. [PMID: 16314830 DOI: 10.1038/sj.onc.1209305] [Cited by in Crossref: 75] [Cited by in F6Publishing: 74] [Article Influence: 4.7] [Reference Citation Analysis]
203 Zhou Y, Dai DL, Martinka M, Su M, Zhang Y, Campos EI, Dorocicz I, Tang L, Huntsman D, Nelson C, Ho V, Li G. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124:1044-52. [PMID: 15854047 DOI: 10.1111/j.0022-202X.2005.23680.x] [Cited by in Crossref: 88] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
204 Shevde LA, Samant RS, Paik JC, Metge BJ, Chambers AF, Casey G, Frost AR, Welch DR. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis 2006;23:123-33. [PMID: 16830223 DOI: 10.1007/s10585-006-9013-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 4.3] [Reference Citation Analysis]
205 Hsu KH, Tsai HW, Lin PW, Hsu YS, Shan YS, Lu PJ. Osteopontin expression is an independent adverse prognostic factor in resectable gastrointestinal stromal tumor and its interaction with CD44 promotes tumor proliferation. Ann Surg Oncol. 2010;17:3043-3052. [PMID: 20549562 DOI: 10.1245/s10434-010-1143-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
206 Hashimoto M, Sun D, Rittling SR, Denhardt DT, Young W. Osteopontin-deficient mice exhibit less inflammation, greater tissue damage, and impaired locomotor recovery from spinal cord injury compared with wild-type controls. J Neurosci 2007;27:3603-11. [PMID: 17392476 DOI: 10.1523/JNEUROSCI.4805-06.2007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
207 Koltai T, Reshkin SJ, Carvalho TMA, Cardone RA. Targeting the Stromal Pro-Tumoral Hyaluronan-CD44 Pathway in Pancreatic Cancer. Int J Mol Sci 2021;22:3953. [PMID: 33921242 DOI: 10.3390/ijms22083953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev 2010;29:295-307. [PMID: 20386958 DOI: 10.1007/s10555-010-9221-8] [Cited by in Crossref: 155] [Cited by in F6Publishing: 146] [Article Influence: 12.9] [Reference Citation Analysis]
209 Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 2008;3:851-7. [PMID: 18670302 DOI: 10.1097/JTO.0b013e318180477b] [Cited by in Crossref: 78] [Cited by in F6Publishing: 33] [Article Influence: 5.6] [Reference Citation Analysis]
210 Moon EJ, Brizel DM, Chi JT, Dewhirst MW. The potential role of intrinsic hypoxia markers as prognostic variables in cancer. Antioxid Redox Signal 2007;9:1237-94. [PMID: 17571959 DOI: 10.1089/ars.2007.1623] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 4.5] [Reference Citation Analysis]
211 Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci 2008;99:1188-94. [PMID: 18422740 DOI: 10.1111/j.1349-7006.2008.00802.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
212 Emani S, Zhang J, Guo L, Guo H, Kuo PC. RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer. Surgery. 2008;143:803-812. [PMID: 18549897 DOI: 10.1016/j.surg.2008.02.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
213 Ramankulov A, Lein M, Kristiansen G, Loening SA, Jung K. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer. Prostate 2007;67:330-40. [DOI: 10.1002/pros.20540] [Cited by in Crossref: 60] [Cited by in F6Publishing: 51] [Article Influence: 4.0] [Reference Citation Analysis]
214 Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, Giaccia AJ, Le QT. Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 2006;24:5291-7. [PMID: 17114663 DOI: 10.1200/JCO.2006.06.8627] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
215 Christensen B, Petersen TE, Sørensen ES. Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J. 2008;411:53-61. [PMID: 18072945 DOI: 10.1042/bj20071021] [Cited by in Crossref: 72] [Cited by in F6Publishing: 32] [Article Influence: 5.1] [Reference Citation Analysis]
216 Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, Basta G, Gastaldelli A, Del Ry S. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up. Cytokine 2017;99:59-65. [PMID: 28711012 DOI: 10.1016/j.cyto.2017.07.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
217 Denhardt D. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124:xvi-xviii. [PMID: 15854023 DOI: 10.1111/j.0022-202X.2005.23708.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
218 Hsieh YH, Margaret Juliana M, Ho KJ, Kuo HC, van der Heyde H, Elmets C, Chang PL. Host-derived osteopontin maintains an acute inflammatory response to suppress early progression of extrinsic cancer cells. Int J Cancer 2012;131:322-33. [PMID: 21826648 DOI: 10.1002/ijc.26359] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
219 Thoms JW, Dal Pra A, Anborgh PH, Christensen E, Fleshner N, Menard C, Chadwick K, Milosevic M, Catton C, Pintilie M, Chambers AF, Bristow RG. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response. Br J Cancer 2012;107:840-6. [PMID: 22871886 DOI: 10.1038/bjc.2012.345] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 3.9] [Reference Citation Analysis]
220 Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biology 2006;16:79-87. [DOI: 10.1016/j.tcb.2005.12.005] [Cited by in Crossref: 463] [Cited by in F6Publishing: 429] [Article Influence: 28.9] [Reference Citation Analysis]
221 Ock CY, Nam AR, Bang JH, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. Gastric Cancer. 2015; Epub ahead of print. [PMID: 26681196 DOI: 10.1007/s10120-015-0583-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
222 Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation. Cancers (Basel) 2020;12:E3379. [PMID: 33203146 DOI: 10.3390/cancers12113379] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
223 Dadarkar SS, Fonseca LC, Mishra PB, Lobo AS, Doshi LS, Dagia NM, Rangasamy AK, Padigaru M. Phenotypic and genotypic assessment of concomitant drug-induced toxic effects in liver, kidney and blood. J Appl Toxicol 2011;31:117-30. [PMID: 20623750 DOI: 10.1002/jat.1562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
224 Hedley BD, Welch DR, Allan AL, Al-Katib W, Dales DW, Postenka CO, Casey G, Macdonald IC, Chambers AF. Downregulation of osteopontin contributes to metastasis suppression by breast cancer metastasis suppressor 1. Int J Cancer. 2008;123:526-534. [PMID: 18470911 DOI: 10.1002/ijc.23542] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
225 Huang F, Cai P, Wang Y, Zhou X, Chen H, Liao W, Mao Y, Zha X, Zhang H, Hu Z. Up-regulation of brain-expressed X-linked 2 is critical for hepatitis B virus X protein-induced hepatocellular carcinoma development. Oncotarget 2017;8:65789-99. [PMID: 29029472 DOI: 10.18632/oncotarget.19477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
226 Li D, Chiu H, Gupta V, Chan DW. Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta 2012;413:1506-11. [PMID: 22722017 DOI: 10.1016/j.cca.2012.06.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
227 Aslam M, Baveja R, Liang OD, Fernandez-Gonzalez A, Lee C, Mitsialis SA, Kourembanas S. Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. Am J Respir Crit Care Med 2009;180:1122-30. [PMID: 19713447 DOI: 10.1164/rccm.200902-0242OC] [Cited by in Crossref: 334] [Cited by in F6Publishing: 195] [Article Influence: 25.7] [Reference Citation Analysis]
228 Russell MD, Young AM, Karri SK. Biomarkers of pediatric brain tumors. Front Pediatr 2013;1:7. [PMID: 24400253 DOI: 10.3389/fped.2013.00007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
229 Visser R, Rico-Llanos GA, Pulkkinen H, Becerra J. Peptides for bone tissue engineering. J Control Release 2016;244:122-35. [PMID: 27794492 DOI: 10.1016/j.jconrel.2016.10.024] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
230 Scherpereel A, Lee YC. Biomarkers for mesothelioma. Curr Opin Pulm Med 2007;13:339-443. [PMID: 17534183 DOI: 10.1097/MCP.0b013e32812144bb] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
231 Jain S, Chakraborty G, Bulbule A, Kaur R, Kundu GC. Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin Ther Targets 2007;11:81-90. [PMID: 17150036 DOI: 10.1517/14728222.11.1.81] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
232 Jin X, Xu H, McGrath MS. Methylglyoxal-bis-guanylhydrazone inhibits osteopontin expression and differentiation in cultured human monocytes. PLoS One 2018;13:e0192680. [PMID: 29538412 DOI: 10.1371/journal.pone.0192680] [Reference Citation Analysis]
233 Chakraborty D, Viveka TS, Arvind K, Shyamsundar V, Kanchan M, Alex SA, Chandrasekaran N, Vijayalakshmi R, Mukherjee A. A facile gold nanoparticle–based ELISA system for detection of osteopontin in saliva: Towards oral cancer diagnostics. Clinica Chimica Acta 2018;477:166-72. [DOI: 10.1016/j.cca.2017.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
234 Park MG, Oh MM, Yoon JH, Park JY, Park HS, Moon DG, Yoon DK. The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: a prospective study. Kaohsiung J Med Sci 2012;28:526-30. [PMID: 23089317 DOI: 10.1016/j.kjms.2012.04.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
235 Hsieh YH, Juliana MM, Chang PL. Establishment and characterization of an osteopontin-null cutaneous squamous cell carcinoma cell line. In Vitro Cell Dev Biol Anim 2010;46:87-91. [PMID: 19915934 DOI: 10.1007/s11626-009-9248-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
236 Kruger TE, Miller AH, Godwin AK, Wang J. Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. Crit Rev Oncol Hematol. 2014;89:330-341. [PMID: 24071501 DOI: 10.1016/j.critrevonc.2013.08.013] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
237 Schytte GN, Christensen B, Bregenov I, Sørensen ES. Ras-transformation reduce FAM20C expression and osteopontin phosphorylation. Biosci Rep 2020;40:BSR20194378. [PMID: 32830861 DOI: 10.1042/BSR20194378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med 2011;13:e15. [PMID: 21545755 DOI: 10.1017/S1462399411001839] [Cited by in Crossref: 67] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
239 Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, Kon S, Maeda M, Uede T, Stitt LW, Chambers AF. New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs. Clinical Chemistry 2009;55:895-903. [DOI: 10.1373/clinchem.2008.117465] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
240 Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. The Lancet Oncology 2005;6:757-64. [DOI: 10.1016/s1470-2045(05)70292-8] [Cited by in Crossref: 216] [Cited by in F6Publishing: 74] [Article Influence: 12.7] [Reference Citation Analysis]
241 Kaomongkolgit R, Manokawinchoke J, Sanchavanakit N, Pavasant P, Sumrejkanchanakij P. Fibronectin supports TNF-alpha-induced osteopontin expression through beta1 integrin and ERK in HN-22 cells. Arch Oral Biol 2010;55:101-7. [PMID: 20056194 DOI: 10.1016/j.archoralbio.2009.12.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
242 Li H, Shen H, Yan G, Zhang Y, Liu M, Fang P, Yu H, Yang P. Site-specific structural characterization of O-glycosylation and identification of phosphorylation sites of recombinant osteopontin. Biochim Biophys Acta 2015;1854:581-91. [PMID: 25450502 DOI: 10.1016/j.bbapap.2014.09.025] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
243 Likui W, Hong W, Shuwen Z, Yuangang Y, Yan W. The potential of osteopontin as a therapeutic target for human colorectal cancer. J Gastrointest Surg 2011;15:652-9. [PMID: 21318445 DOI: 10.1007/s11605-011-1445-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
244 Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep 2008;10:277-82. [PMID: 18778551 DOI: 10.1007/s11912-008-0043-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
245 Li X, Jiang Z, Li X, Zhang X. SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling. Onco Targets Ther 2018;11:1157-71. [PMID: 29535539 DOI: 10.2147/OTT.S137146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
246 Duvall CL, Weiss D, Robinson ST, Alameddine FM, Guldberg RE, Taylor WR. The Role of Osteopontin in Recovery from Hind Limb Ischemia. ATVB 2008;28:290-5. [DOI: 10.1161/atvbaha.107.158485] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
247 Kuznetsov NV, Andersson P, Gradin K, Stein Pv, Dieckmann A, Pettersson S, Hanberg A, Poellinger L. The dioxin/aryl hydrocarbon receptor mediates downregulation of osteopontin gene expression in a mouse model of gastric tumourigenesis. Oncogene 2005;24:3216-22. [PMID: 15735673 DOI: 10.1038/sj.onc.1208529] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
248 Ingale Y, Routray S, Kheur SM, Kheur M, Mohanty N. Evaluating the efficacy of osteopontin expression as a prognostic marker in oral squamous cell carcinoma in the Indian subpopulation. J Oral Maxillofac Pathol 2014;18:S11-5. [PMID: 25364158 DOI: 10.4103/0973-029X.141327] [Reference Citation Analysis]
249 Simões CC, Call MK, Corrêa ZM, Spaulding AG, Augsburger JJ. Clinical and histopathological features and immunoreactivity of human choroidal and ciliary melanomas as prognostic factors for metastasis and death. Graefes Arch Clin Exp Ophthalmol 2011;249:1795-803. [DOI: 10.1007/s00417-011-1769-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
250 Mitra A, Conway C, Walker C, Cook M, Powell B, Lobo S, Chan M, Kissin M, Layer G, Smallwood J, Ottensmeier C, Stanley P, Peach H, Chong H, Elliott F, Iles MM, Nsengimana J, Barrett JH, Bishop DT, Newton-Bishop JA. Melanoma sentinel node biopsy and prediction models for relapse and overall survival. Br J Cancer 2010;103:1229-36. [PMID: 20859289 DOI: 10.1038/sj.bjc.6605849] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
251 Ramankulov A, Lein M, Kristiansen G, Meyer HA, Loening SA, Jung K. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma. J Cancer Res Clin Oncol. 2007;133:643-652. [PMID: 17479289 DOI: 10.1007/s00432-007-0215-z] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 2.7] [Reference Citation Analysis]
252 Kim J, Ki SS, Lee SD, Han CJ, Kim YC, Park SH, Cho SY, Hong YJ, Park HY, Lee M. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol. 2006;101:2051-2059. [PMID: 16848813 DOI: 10.1111/j.1572-0241.2006.00679.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 91] [Article Influence: 5.6] [Reference Citation Analysis]
253 Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: Potential clinical applications in cancer (Review). Int J Mol Med 2017;39:1327-37. [PMID: 28440483 DOI: 10.3892/ijmm.2017.2964] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 7.2] [Reference Citation Analysis]
254 Melen-Mucha G, Niedziela A, Mucha S, Motylewska E, Lawnicka H, Komorowski J, Stepien H. Elevated peripheral blood plasma concentrations of tie-2 and angiopoietin 2 in patients with neuroendocrine tumors. Int J Mol Sci 2012;13:1444-60. [PMID: 22408401 DOI: 10.3390/ijms13021444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
255 Takafuji V, Forgues M, Unsworth E, Goldsmith P, Wang XW. An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene. 2007;26:6361-6371. [PMID: 17452979 DOI: 10.1038/sj.onc.1210463] [Cited by in Crossref: 124] [Cited by in F6Publishing: 128] [Article Influence: 8.3] [Reference Citation Analysis]
256 Songtao Q, Guanglong H, Jun P, Jia L, Xi’an Z, Luxiong F, Baoguo L, Wei M, Yongming Z, Xiaojun L. Involvement of osteopontin as a core protein in craniopharyngioma calcification formation. J Neurooncol 2010;98:21-30. [DOI: 10.1007/s11060-009-0053-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
257 Toy H, Yavas O, Eren O, Genc M, Yavas C. Correlation between osteopontin protein expression and histological grade of astrocytomas. Pathol Oncol Res 2009;15:203-7. [PMID: 19048398 DOI: 10.1007/s12253-008-9130-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
258 Luo X, Ruhland MK, Pazolli E, Lind AC, Stewart SA. Osteopontin stimulates preneoplastic cellular proliferation through activation of the MAPK pathway. Mol Cancer Res 2011;9:1018-29. [PMID: 21673011 DOI: 10.1158/1541-7786.MCR-10-0472] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
259 Aponte-López A, Enciso J, Muñoz-Cruz S, Fuentes-Pananá EM. An In Vitro Model of Mast Cell Recruitment and Activation by Breast Cancer Cells Supports Anti-Tumoral Responses. Int J Mol Sci 2020;21:E5293. [PMID: 32722549 DOI: 10.3390/ijms21155293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
260 Ishigamori R, Komiya M, Takasu S, Mutoh M, Imai T, Takahashi M. Osteopontin Deficiency Suppresses Intestinal Tumor Development in Apc-Deficient Min Mice. Int J Mol Sci 2017;18:E1058. [PMID: 28505114 DOI: 10.3390/ijms18051058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
261 Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, Frantzi M. Proteomics biomarkers for solid tumors: Current status and future prospects. Mass Spectrom Rev 2019;38:49-78. [PMID: 29889308 DOI: 10.1002/mas.21572] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
262 Lu Y, Yi Y, Liu P, Wen W, James M, Wang D, You M. Common human cancer genes discovered by integrated gene-expression analysis. PLoS One 2007;2:e1149. [PMID: 17989776 DOI: 10.1371/journal.pone.0001149] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 3.8] [Reference Citation Analysis]
263 Schultz J, Lorenz P, Ibrahim SM, Kundt G, Gross G, Kunz M. The functional −443T/C osteopontin promoter polymorphism influences osteopontin gene expression in melanoma cells via binding of c-Myb transcription factor. Mol Carcinog 2009;48:14-23. [DOI: 10.1002/mc.20452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
264 Soikkeli J, Lukk M, Nummela P, Virolainen S, Jahkola T, Katainen R, Harju L, Ukkonen E, Saksela O, Hölttä E. Systematic search for the best gene expression markers for melanoma micrometastasis detection. J Pathol 2007;213:180-9. [PMID: 17891747 DOI: 10.1002/path.2229] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
265 Starr JS, Jiang L, Li Z, Qiu Y, Menke DM, Tun HW. CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement. Clin Lymphoma Myeloma Leuk 2013;13:597-601. [PMID: 23810243 DOI: 10.1016/j.clml.2013.05.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
266 Shao L, Zhang B, Wang L, Wu L, Kan Q, Fan K. MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells. Biochemical and Biophysical Research Communications 2017;493:1478-84. [DOI: 10.1016/j.bbrc.2017.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
267 Raja R, Kale S, Thorat D, Soundararajan G, Lohite K, Mane A, Karnik S, Kundu GC. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis. Oncogene. 2014;33:2053-2064. [PMID: 23728336 DOI: 10.1038/onc.2013.171] [Cited by in Crossref: 72] [Cited by in F6Publishing: 73] [Article Influence: 8.0] [Reference Citation Analysis]
268 Hsu KH, Tsai HW, Lin PW, Hsu YS, Lu PJ, Shan YS. Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors. World J Surg Oncol 2014;12:189. [PMID: 24947165 DOI: 10.1186/1477-7819-12-189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
269 Sedivy R, Peters K, Kl�ppel G. Osteopontin expression in ductal adenocarcinomas and undifferentiated carcinomas of the pancreas. Virchows Arch 2005;446:41-5. [DOI: 10.1007/s00428-004-1142-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
270 Tokuda K, Morine Y, Miyazaki K, Yamada S, Saito Y, Nishi M, Tokunaga T, Ikemoto T, Imura S, Shimada M. The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma. Oncotarget 2021;12:333-43. [PMID: 33659044 DOI: 10.18632/oncotarget.27881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
271 Kilic G, Wang J, Sosa-Pineda B. Osteopontin is a novel marker of pancreatic ductal tissues and of undifferentiated pancreatic precursors in mice. Dev Dyn 2006;235:1659-67. [PMID: 16518820 DOI: 10.1002/dvdy.20729] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
272 Scheil-Bertram S, Kappler R, von Baer A, Hartwig E, Sarkar M, Serra M, Brüderlein S, Westhoff B, Melzner I, Bassaly B, Herms J, Hugo HH, Schulte M, Möller P. Molecular profiling of chordoma. Int J Oncol 2014;44:1041-55. [PMID: 24452533 DOI: 10.3892/ijo.2014.2268] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
273 Said HM, Katzer A, Flentje M, Vordermark D. Response of the plasma hypoxia marker osteopontin to in vitro hypoxia in human tumor cells. Radiother Oncol. 2005;76:200-205. [PMID: 16024111 DOI: 10.1016/j.radonc.2005.06.023] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
274 Cioroianu AI, Stinga PI, Sticlaru L, Cioplea MD, Nichita L, Popp C, Staniceanu F. Tumor Microenvironment in Diffuse Large B-Cell Lymphoma: Role and Prognosis. Anal Cell Pathol (Amst) 2019;2019:8586354. [PMID: 31934533 DOI: 10.1155/2019/8586354] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
275 Pawelek JM, Chakraborty AK. The cancer cell--leukocyte fusion theory of metastasis. Adv Cancer Res. 2008;101:397-444. [PMID: 19055949 DOI: 10.1016/s0065-230x(08)00410-7] [Cited by in Crossref: 104] [Cited by in F6Publishing: 67] [Article Influence: 8.0] [Reference Citation Analysis]
276 Beckebaum S, Chen X, Sotiropoulos GC, Radtke A, Daoudaki M, Baba HA, Wohlschlaeger J, Broelsch CE, Gerken G, Cicinnati VR. Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection. Transplant Proc. 2008;40:3182-3184. [PMID: 19010227 DOI: 10.1016/j.transproceed.2008.08.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
277 Min TU, Sheng LY, Chao C, Jian T, Guang GS, Hua LG. Correlation between osteopontin and caveolin-1 in the pathogenesis and progression of osteoarthritis. Exp Ther Med 2015;9:2059-64. [PMID: 26136936 DOI: 10.3892/etm.2015.2433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
278 Matušan-Ilijaš K, Damante G, Fabbro D, Dorđević G, Hadžisejdić I, Grahovac M, Avirović M, Grahovac B, Jonjić N, Lučin K. EGFR expression is linked to osteopontin and Nf-κB signaling in clear cell renal cell carcinoma. Clin Transl Oncol 2013;15:65-71. [PMID: 22855173 DOI: 10.1007/s12094-012-0889-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
279 Whiteaker JR, Zhang H, Zhao L, Wang P, Kelly-Spratt KS, Ivey RG, Piening BD, Feng LC, Kasarda E, Gurley KE, Eng JK, Chodosh LA, Kemp CJ, McIntosh MW, Paulovich AG. Integrated pipeline for mass spectrometry-based discovery and confirmation of biomarkers demonstrated in a mouse model of breast cancer. J Proteome Res 2007;6:3962-75. [PMID: 17711321 DOI: 10.1021/pr070202v] [Cited by in Crossref: 147] [Cited by in F6Publishing: 141] [Article Influence: 9.8] [Reference Citation Analysis]
280 Bache M, Reddemann R, Said HM, Holzhausen H, Taubert H, Becker A, Kuhnt T, Hänsgen G, Dunst J, Vordermark D. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: Prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1α-related markers, and hemoglobin levels. International Journal of Radiation Oncology*Biology*Physics 2006;66:1481-7. [DOI: 10.1016/j.ijrobp.2006.07.1376] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
281 Måseide K, Kalliomäki T, Hill RP. Microenvironmental Effects on Tumour Progression and Metastasis. In: Meadows GG, editor. Integration/Interaction of Oncologic Growth. Berlin/Heidelberg: Springer-Verlag; 2005. pp. 1-22. [DOI: 10.1007/1-4020-3414-8_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
282 Ogata T, Ueyama T, Nomura T, Asada S, Tagawa M, Nakamura T, Takahashi T, Matsubara H, Oh H. Osteopontin is a myosphere-derived secretory molecule that promotes angiogenic progenitor cell proliferation through the phosphoinositide 3-kinase/Akt pathway. Biochemical and Biophysical Research Communications 2007;359:341-7. [DOI: 10.1016/j.bbrc.2007.05.104] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
283 Vashisht S, Bagler G. An approach for the identification of targets specific to bone metastasis using cancer genes interactome and gene ontology analysis. PLoS One 2012;7:e49401. [PMID: 23166660 DOI: 10.1371/journal.pone.0049401] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]